Hormographiella aspergillata: an emerging mould in acute leukaemia patients?
We describe three invasive mould infections due to Hormographiella aspergillata occurring within 1 year in patients undergoing treatment for acute leukaemia. All patients presented with pulmonary infiltrates; one patient additionally had cerebral and ocular involvement. Diagnostic procedures included bronchoalveolar lavage in all, and video-assisted thoracoscopic surgery in two patients. Susceptibility testing was performed by E-test and detected low minimal inhibitory concentrations for voriconazole and amphotericin B. All patients received systemic antifungal therapy; however, all of them died. Despite this cluster of three cases of an unusual mould infection, no hospital source was detected.
Conen
A
A
Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, Aarau, Switzerland. anna.conen@ksa.ch
Weisser
M
M
Hohler
D
D
Frei
R
R
Stern
M
M
D000328:Adult; D000363:Agaricales / Q000302:isolation & purification*; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D020314:Central Nervous System Fungal Infections / Q000382:microbiology / Q000473:pathology; D021821:Communicable Diseases, Emerging / Q000453:epidemiology* / Q000382:microbiology; D005128:Eye Diseases / Q000382:microbiology / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008172:Lung Diseases, Fungal / Q000382:microbiology / Q000473:pathology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009181:Mycoses / Q000453:epidemiology* / Q000382:microbiology
D000935:Antifungal Agents